Abstract
A novel series of 5-((4-aminopiperidin-1-yl)methyl)-pyrrolo[2,1-f][1,2,4]triazin-4-amines with small aniline substituents at the C4 position were optimized for dual EGFR and HER2 protein tyrosine kinase inhibition. Compound 8l exhibited promising oral efficacy in both EGFR and HER2-driven human tumor xenograft models.
Copyright © 2010 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Antineoplastic Agents / chemistry*
-
Antineoplastic Agents / pharmacokinetics
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Cell Line, Tumor
-
Colonic Neoplasms / drug therapy
-
ErbB Receptors / antagonists & inhibitors*
-
ErbB Receptors / metabolism
-
Humans
-
Male
-
Mice
-
Mice, Inbred BALB C
-
Models, Molecular
-
Neoplasms / drug therapy*
-
Neoplasms / enzymology
-
Protein-Tyrosine Kinases / chemistry*
-
Protein-Tyrosine Kinases / pharmacokinetics
-
Protein-Tyrosine Kinases / pharmacology
-
Protein-Tyrosine Kinases / therapeutic use*
-
Pyrroles / chemistry
-
Pyrroles / pharmacokinetics
-
Pyrroles / pharmacology
-
Pyrroles / therapeutic use
-
Receptor, ErbB-2 / antagonists & inhibitors*
-
Receptor, ErbB-2 / metabolism
-
Stomach Neoplasms / drug therapy
-
Triazines / chemistry
-
Triazines / pharmacokinetics
-
Triazines / pharmacology
-
Triazines / therapeutic use
-
Xenograft Model Antitumor Assays
Substances
-
Antineoplastic Agents
-
Pyrroles
-
Triazines
-
ErbB Receptors
-
Protein-Tyrosine Kinases
-
Receptor, ErbB-2